Surrozen (NASDAQ:SRZN) Major Shareholder Buys $110,404.77 in Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III acquired 5,523 shares of the business’s stock in a transaction that occurred on Wednesday, January 14th. The shares were purchased at an average cost of $19.99 per share, for a total transaction of $110,404.77. Following the completion of the transaction, the insider directly owned 999,429 shares in the company, valued at $19,978,585.71. The trade was a 0.56% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The stock was purchased at an average cost of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III bought 15,100 shares of Surrozen stock. The stock was purchased at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The shares were purchased at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III purchased 5,266 shares of Surrozen stock. The shares were purchased at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The stock was purchased at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Stock Performance

SRZN stock remained flat at $20.00 during midday trading on Thursday. The company had a trading volume of 28,721 shares, compared to its average volume of 83,852. The business has a 50 day simple moving average of $18.38 and a 200-day simple moving average of $13.80. Surrozen, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $24.94. The stock has a market capitalization of $171.40 million, a P/E ratio of -0.90 and a beta of 0.58.

Surrozen (NASDAQ:SRZN) last posted its earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The business had revenue of $0.98 million during the quarter. Surrozen had a negative return on equity of 4,055.04% and a negative net margin of 2,909.10%. On average, equities analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have issued reports on SRZN. Lifesci Capital upgraded shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. Finally, Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $32.00.

Institutional Investors Weigh In On Surrozen

Hedge funds and other institutional investors have recently made changes to their positions in the business. Braidwell LP bought a new position in shares of Surrozen in the 2nd quarter worth approximately $1,252,000. Stempoint Capital LP increased its holdings in Surrozen by 185.1% during the second quarter. Stempoint Capital LP now owns 686,539 shares of the company’s stock valued at $6,138,000 after buying an additional 445,713 shares during the last quarter. Stonepine Capital Management LLC increased its holdings in Surrozen by 7.1% during the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock valued at $2,736,000 after buying an additional 20,247 shares during the last quarter. Vanguard Group Inc. raised its position in Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after acquiring an additional 47,468 shares during the period. Finally, Acuta Capital Partners LLC boosted its stake in shares of Surrozen by 5.0% during the 3rd quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock worth $2,299,000 after acquiring an additional 8,415 shares during the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Surrozen Company Profile

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.